Buscar
Beam Therapeutics Inc
BEAMAñadir a la lista de seguimiento
25.520USD
-0.970-3.66%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.63BCap. mercado
PérdidaP/E TTM
Más Datos de Beam Therapeutics Inc Compañía
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Información de Beam Therapeutics Inc
Símbolo de cotizaciónBEAM
Nombre de la empresaBeam Therapeutics Inc
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoEvans (John M)
Número de empleados483
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección238 Main Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono18573278775
Sitio Webhttps://beamtx.com/
Símbolo de cotizaciónBEAM
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoEvans (John M)
Ejecutivos de Beam Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
178.91K
+19.85%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
26.42K
-1.41%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
Ms. Kathleen E. Walsh
Ms. Kathleen E. Walsh
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
178.91K
+19.85%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
26.42K
-1.41%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Beam Therapeutics Inc?
Los cinco principales accionistas de Beam Therapeutics Inc son: Dr. Giuseppe Ciaramella, Ph.D.
¿Cuántas instituciones poseen acciones de Beam Therapeutics Inc (BEAM)?
A fecha de 2026Q1, 560 instituciones poseen acciones de Beam Therapeutics Inc, con un valor de mercado combinado de aproximadamente 106.16M, lo que representa el 103.20% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -6468210.00.